Loading
A second lutetium radioligand for neuroendocrine tumours that beat the standard pill everolimus in a head-to-head trial and is awaiting an FDA decision.
COMPETE (Lancet 2025; 309 patients, grade 1-2 GEP-NETs): PFS 23.9 vs 14.1 months versus everolimus (HR 0.67); response rate higher; interim OS 63.4 vs 58.7 months, a difference that did not reach statistical significance (HR 0.78). Uses non-carrier-added 177Lu from ITM's own supply. NDA accepted with PDUFA 28 August 2026. COMPOSE (grade 2-3, versus CAPTEM/everolimus/FOLFOX) ongoing.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
DOTATOC peptide (SSTR2 agonist) chelating 177Lu; four cycles of 7.5 GBq every 3 months. Connects to Somatostatin receptor 2.
1.177Lu-edotreotide binds Somatostatin receptor 2 on the cancer cell or is taken up by it.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"177Lu-edotreotide" OR ABSTRACT:"177Lu-edotreotide" OR TITLE:"ITM-11" OR ABSTRACT:"ITM-11" OR TITLE:"n.c.a. 177Lu-DOTATOC" OR ABSTRACT:"n.c.a. 177Lu-DOTATOC") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 177Lu-edotreotide, not a curated reading list.
Shares COMPETE, Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Grade 3 well-differentiated neuroendocrine tumour, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares COMPETE, Somatostatin receptor 2, Radioligand therapy (beta emitters), Neuroendocrine tumours.
Shares SSTR PET → PRRT, Grade 3 well-differentiated neuroendocrine tumour, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2.
Shares Grade 3 well-differentiated neuroendocrine tumour, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.